Akero Therapeutics

View All

alzheimer's
Lilly remunerates AC Immune; Akero adds $70M; Ra Pharma $100M

Lilly remunerates AC Immune USD 81 Million for preclinical Alzheimer’s drug Eli Lilly has remunerated USD 81 million upfront for the global rights to AC Immune’s tau aggregation inhibitors in Alzheimer’s disease. The agreement provides Lilly ownership of a small molecule that has prevented tau aggregation in preclin...

Find More